ARTICLE
10 May 2017

Tsang Featured In The Pink Sheet On Post-Brexit Pharmaceutical Regulations

AP
Arnold & Porter

Contributor

Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
Pharma Firms Urged To Push For Post-Brexit Regulatory Equivalence Deal
United States Food, Drugs, Healthcare, Life Sciences

Life Sciences and Healthcare Regulatory partner Lincoln Tsang was featured in a recent The Pink Sheet article, "Pharma Firms Urged To Push For Post-Brexit Regulatory Equivalence Deal," which examines the ramifications of a post-Brexit regulatory equivalence agreement between the UK and EU on the pharmaceutical industry.

» Read the full article (subscription required). 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More